Hantz Financial Services Inc. lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 27.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,077 shares of the pharmaceutical company’s stock after selling 4,587 shares during the period. Hantz Financial Services Inc.’s holdings in Vertex Pharmaceuticals were worth $6,314,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $11,975,849,000. State Street Corp grew its position in Vertex Pharmaceuticals by 1.2% in the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock valued at $5,896,910,000 after buying an additional 141,320 shares during the last quarter. Wellington Management Group LLP grew its position in Vertex Pharmaceuticals by 1.1% in the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock valued at $1,613,209,000 after buying an additional 35,069 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Vertex Pharmaceuticals by 1.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock valued at $1,533,248,000 after buying an additional 29,287 shares during the period. Finally, Bank of America Corp DE acquired a new position in Vertex Pharmaceuticals in the 2nd quarter valued at $1,509,651,000. Institutional investors and hedge funds own 90.96% of the company’s stock.
Vertex Pharmaceuticals Stock Down 0.2%
Vertex Pharmaceuticals stock opened at $537.79 on Tuesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 1.89. Vertex Pharmaceuticals Incorporated has a 1-year low of $412.27 and a 1-year high of $568.67. The company has a market cap of $136.35 billion, a PE ratio of 34.61, a price-to-earnings-growth ratio of 2.87 and a beta of 0.28. The stock’s 50 day moving average price is $522.20 and its 200 day moving average price is $484.14.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). The business had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The company’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.80 EPS. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current fiscal year.
Insider Activity at Vertex Pharmaceuticals
In other news, EVP Charles Wagner, Jr. sold 15,286 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $547.87, for a total transaction of $8,374,740.82. Following the transaction, the executive vice president directly owned 31,764 shares of the company’s stock, valued at $17,402,542.68. This represents a 32.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.20% of the company’s stock.
Analysts Set New Price Targets
A number of equities analysts have commented on VRTX shares. Morgan Stanley cut their price objective on shares of Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating for the company in a research report on Tuesday, November 3rd. Evercore lifted their target price on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a report on Wednesday, September 2nd. Leerink Partners assumed coverage on shares of Vertex Pharmaceuticals in a research note on Monday, September 21st. They set an “outperform” rating and a $594.00 price target on the stock. Daiwa Securities Group increased their price target on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Stifel Nicolaus increased their price target on shares of Vertex Pharmaceuticals from $500.00 to $563.00 and gave the stock a “hold” rating in a report on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $596.44.
Read Our Latest Stock Report on VRTX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Read More
- Five stocks we like better than Vertex Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
